Oppenheimer Holdings, Inc. initiated coverage on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research report report published on Monday. The brokerage issued a buy rating and a $27.00 target price on the biotechnology company’s stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.83) EPS, Q4 2017 earnings at ($0.88) EPS, FY2017 earnings at ($3.49) EPS, Q1 2018 earnings at ($0.87) EPS, Q2 2018 earnings at ($0.81) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.49) EPS, FY2018 earnings at ($2.81) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at $1.46 EPS and FY2021 earnings at $3.30 EPS.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a report on Thursday, October 26th. Noble Financial restated a buy rating and issued a $24.00 price target on shares of Heron Therapeutics in a research report on Friday, October 6th. Northland Securities began coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They issued an outperform rating and a $40.00 price target for the company. Mizuho began coverage on Heron Therapeutics in a research report on Tuesday, September 26th. They issued a buy rating and a $28.00 price target for the company. Finally, BidaskClub upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Saturday, August 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $28.36.

Heron Therapeutics (NASDAQ HRTX) traded up $0.50 during mid-day trading on Monday, hitting $16.05. 706,602 shares of the company were exchanged, compared to its average volume of 636,486. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.82 and a quick ratio of 2.72.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. research analysts predict that Heron Therapeutics will post -3.49 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Heron Therapeutics, Inc. (HRTX) Coverage Initiated at Oppenheimer Holdings, Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-coverage-initiated-at-oppenheimer-holdings-inc/1676671.html.

Several large investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC lifted its position in shares of Heron Therapeutics by 2.3% during the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 771 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Heron Therapeutics by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its position in shares of Heron Therapeutics by 10.2% during the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,724 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.